智通财经APP讯，轩竹生物-B(02575)发布公告，本公司自主研发的创新药吡洛西利片(商品名：轩悦宁®)首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录( 2025年 )》(2025国家基本医保目录)。 2025国家基本医保目录将于2026年1月1日正式执行。
本次医保谈判结果有助于本公司进一步提高轩悦宁®在患者中的可负担性和可及性，有利于进一步推动该药物的市场推广、提升销售规模，对本公司的长期经营发展具有积极影响。本公司将积极配合推进医保政策落地，持续推进医院准入工作、拓展核心市场及扩大市场的覆盖，以期不断提升患者的用药可及性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.